Frankfurt - Delayed Quote • EUR
Iovance Biotherapeutics, Inc. (2LB.F)
At close: April 25 at 8:04 AM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-361,820.00
-361,820.00
-292,757.00
-227,941.00
-205,134.00
Investing Cash Flow
-155,242.00
-155,242.00
256,455.00
132.00
-317,853.00
Financing Cash Flow
462,959.00
462,959.00
190,150.00
239,268.00
576,422.00
End Cash Position
181,318.00
181,318.00
238,161.00
84,313.00
72,854.00
Capital Expenditure
-22,290.00
-22,290.00
-20,425.00
-37,574.00
-46,791.00
Issuance of Capital Stock
463,281.00
463,281.00
189,502.00
203,156.00
567,043.00
Issuance of Debt
--
--
--
1,000.00
--
Free Cash Flow
-384,110.00
-384,110.00
-313,182.00
-265,515.00
-251,925.00
12/31/2020 - 3/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
XBIOW Xenetic Biosciences, Inc.
7.46
-17.11%
ATNFW 180 Life Sciences Corp.
0.0090
-4.26%
GLPG.AS Galapagos NV
26.56
-2.06%
IFRX InflaRx N.V.
1.3900
+2.21%
NOV.DE Novo Nordisk A/S
116.20
-1.36%
IONS Ionis Pharmaceuticals, Inc.
41.84
-1.44%
PRME Prime Medicine, Inc.
4.3000
-8.51%
ATOS Atossa Therapeutics, Inc.
1.5200
+1.33%
SRNE Sorrento Therapeutics, Inc.
0.0200
0.00%
AGEN Agenus Inc.
8.30
+11.86%